{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-013687","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.918714+00:00","generated_at":"2026-06-03T05:32:26.206154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal","bullets":["Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.","Net loss narrowed to $3.4M ($0.20 per share) compared to $4.4M ($0.33) in Q1 2023.","CMS issued final Medicare payment determination for Ekso Indego Personal, enabling reimbursement.","Sold 29 EksoHealth units in Q1; cash and restricted cash $8.8M at March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-013687","json":"https://secwatch.observer/filing/0001437749-24-013687.json","markdown":"https://secwatch.observer/filing/0001437749-24-013687.md","text":"https://secwatch.observer/filing/0001437749-24-013687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/0001437749-24-013687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/ekso20240425_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:32:26.206154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bfa84daeaf7191956244e2fe0c021578dbbdbea","claim":"EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2024 results: revenue $3.8 million, net income $3.4 million, EPS $0.20 per basic and diluted share.","evidence_excerpt":"● Received final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for Ekso Indego Personal ● Reported revenues of $3.8 million for the first quarter of 2024 ● Achieved gross margin of 52% for the quarter ended March 31, 2024 ● Sold a total of 29 EksoHealth units in the first quarter of 2024 “We started","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/0001437749-24-013687-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"$3.4 million"},{"label":"EPS","value":"$0.20 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}